MUC16 and neoplasm: In relation to tumor-immune cell interactions, 6 of the 10 CMS change-associated SCGs (MYO1B, POLQ, MKI67, COL11A1, MUC16, FRYL) were associated with a CMS1 “immune”-type increase, and 6 (MYO1B, DSCAML1, PCDH10, MUC16, FRYL, DNAH17) may be involved in cell-cell interactions and/or motility, which facilitate immune infiltration.